Chelators at the cancer coalface: desferrioxamine to triapine and beyond

Yu Yu, Jacky Wong, David B. Lovejoy, Danuta S. Kalinowski, Des R. Richardson*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

153 Citations (Scopus)

Abstract

The importance of iron and copper in cancer biology has been well established. Iron plays a fundamental role in cellular proliferation and copper has been shown to be a significant cofactor for angiogenesis. Early observations with the chelator used for the treatment of iron overload, desferrioxamine, showed that it had promise as an anticancer agent. These results sparked great interest in the possibility of developing more effective iron chelators for cancer therapy. The recent entry into clinical trials of the iron-binding drug,Triapine, provides evidence of the potential of this antitumor strategy. Likewise, chelators originally designed to treat disorders of copper overload, such as penicillamine, trientine, and tetrathiomolybdate, have also emerged as potential anticancer drugs, as they are able to target the key angiogenic cofactor, copper. In this review, we will discuss the development of these and other chelators that show potential as anticancer agents.

Original languageEnglish
Pages (from-to)6876-6883
Number of pages8
JournalClinical Cancer Research
Volume12
Issue number23
DOIs
Publication statusPublished - 1 Dec 2006
Externally publishedYes

Keywords

  • PYRIDOXAL ISONICOTINOYL HYDRAZONE
  • RIBONUCLEOTIDE REDUCTASE INHIBITOR
  • EFFECTIVE ANTIPROLIFERATIVE AGENTS
  • SELECTIVE ANTITUMOR-ACTIVITY
  • SQUAMOUS-CELL CARCINOMA
  • PHASE-II TRIAL
  • IRON CHELATORS
  • 3-AMINOPYRIDINE-2-CARBOXALDEHYDE THIOSEMICARBAZONE
  • HEPATOCELLULAR-CARCINOMA
  • TUMOR ANGIOGENESIS

Cite this